Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD)

BMC Gastroenterology

Volumn 10, Issue , 2010, Pages

  Raszeja Wyszomirska, Joanna ^a   Szymanik, Barbara ^b   Ławniczak, Małgorzata ^a   Kajor, Maciej ^c   Chwist, Alina ^c   Milkiewicz, Piotr ^a   Hartleb, Marek ^c  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b WEST POMERANIAN UNIVERSITY OF TECHNOLOGY   (Poland)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; POLAND; PREDICTION; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; BIOPSY; BLOOD; COHORT ANALYSIS; FATTY LIVER; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; LIVER; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; VALIDATION STUDY;

ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOPSY; BLOOD GLUCOSE; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLAND; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 77953956160     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-10-67     Document Type: Article

References (15)

1. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, Fargion S. Risk of severe level disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008, 48:792-798. 10.1002/hep.22429, 18752331.
2. Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007, 22:293-303. 10.1111/j.1440-1746.2007.04824.x, 17295757.
3. Tarher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007, 30:1212-1218. 10.2337/dc06-2247, 17277038.
4. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwandet-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008, 57:1441-1447. 10.1136/gut.2007.146019, 18390575.
5. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TB, Day CP. The NAFLD Fibrosis Score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45:846-854. 10.1002/hep.21496, 17393509.
6. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008, 47:455-460. 10.1002/hep.21984, 18038452.
7. Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006, 55:1650-1660. 10.1136/gut.2006.091454, 1860097, 17047111.
8. Fujii H, Enomoto M, Fukushima W, Tamori A, Sakaguchi H, Kawada N. Applicability of BARD score to Japanese patients with NAFLD. Gut 2009, 58:1566-1567. 10.1136/gut.2009.182758, 19834122.
9. Shah A, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, . NASH Clinical Research Network Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009, 7(10):1104-1112. 10.1016/j.cgh.2009.05.033, 19523535, NASH Clinical Research Network.
10. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Human Pathology 1989, 20:594-8. 10.1016/0046-8177(89)90249-9, 2656500.
11. Angulo P, Alba LM, Petrovic LM. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J.Hepatol 2004, 41:943-9. 10.1016/j.jhep.2004.08.020, 15582127.
12. Chwist A, Hartleb M, Kacperek-Hartleb T, Kajor M, Kukla M, Żwirska-Korczala K. Insulin resistance may better identify fibrosis in non-alcoholic fatty liver disease (NAFLD) than serum adipocytokines. J Hepatol 2009, 50:S358.
13. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850. 10.2337/diabetes.50.8.1844, 11473047.
14. Haukeland JW, Konopski Z, Linnestad P, Azimy S, Marit Løberg E, Haaland T, Birkeland K, Bjøro K. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol 2005, 40(12):1469-77. 10.1080/00365520500264953, 16293559.
15. Tarantino G, Conca P, Riccio A, Tarantino M, Di Minno MN, Chianese D, Pasanisi F, Contaldo F, Scopacasa F, Capone D. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign?. J Transl Med 2008, 6:72-79. 10.1186/1479-5876-6-72, 2611972, 19038040.